[go: up one dir, main page]

BR112013010535A2 - composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer - Google Patents

composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer

Info

Publication number
BR112013010535A2
BR112013010535A2 BR112013010535A BR112013010535A BR112013010535A2 BR 112013010535 A2 BR112013010535 A2 BR 112013010535A2 BR 112013010535 A BR112013010535 A BR 112013010535A BR 112013010535 A BR112013010535 A BR 112013010535A BR 112013010535 A2 BR112013010535 A2 BR 112013010535A2
Authority
BR
Brazil
Prior art keywords
cadherin
methods
polypeptides
cells
subdomains
Prior art date
Application number
BR112013010535A
Other languages
English (en)
Inventor
Kerry O'banion M
Brouxhon Sabine
Kyrkanides Stephanos
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of BR112013010535A2 publication Critical patent/BR112013010535A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)

Abstract

composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer. a presente invenção é baseada, em parte, na nossa descoberta que ter como alvo epítopos dentro de um ou mais dos subdomínios ec2-ec5 de e-caderina resulta na morte de células de tumor derivadas do epitélio, mas não na morte de células epiteliais normais, saudáveis ou células não-epiteliais, incluindo células endoteliais e fibroblastos. nesse sentido, as composições da invenção incluem polipeptídeos tendo uma sequencia de aminoácido de um ou mais dos subdomínios ec2-ec5 de e-caderina e variantes biologicamente ativos dos mesmos; vetores de expressão e células para expressar tais polipeptídeos; e agentes (por exemplo, anticorpos) que se direcionam aos subdomínios ec2-ec5. os métodos da invenção incluem métodos de identificar e produzir polipeptídeos tendo uma sequencia de aminoácido de um ou mais dos subdomínios ec2-ec5 de e-caderina ou um variante biologicamente ativo dos mesmos; métodos de geração de agentes, tais como anticorpos, que se destinam a estes polipeptídeos, e métodos de administração de tais agentes ou de provocar sua produção in vivo para tratar cânceres epiteliais ou reduzir o risco de sua ocorrência ou recorrência.
BR112013010535A 2010-10-27 2011-10-27 composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer BR112013010535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40736710P 2010-10-27 2010-10-27
PCT/US2011/058076 WO2012058418A2 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Publications (1)

Publication Number Publication Date
BR112013010535A2 true BR112013010535A2 (pt) 2017-11-07

Family

ID=45994754

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010535A BR112013010535A2 (pt) 2010-10-27 2011-10-27 composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer

Country Status (13)

Country Link
US (4) US20130287784A1 (pt)
EP (1) EP2632489B1 (pt)
JP (1) JP6243737B2 (pt)
KR (1) KR20140075639A (pt)
CN (1) CN103582494A (pt)
AU (1) AU2011319777B2 (pt)
BR (1) BR112013010535A2 (pt)
CA (1) CA2816358A1 (pt)
ES (1) ES2784385T3 (pt)
MX (2) MX357167B (pt)
RU (1) RU2013123792A (pt)
SG (3) SG189547A1 (pt)
WO (1) WO2012058418A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
RU2014141114A (ru) * 2012-03-15 2016-05-10 Дзе Рисерч Фаундейшн Фор Дзе Стейт Юниверсити Оф Нью Йорк Комбинированные виды терапии с использованием ингибиторов внеклеточного домена е-кадгерина
US9411750B2 (en) * 2012-07-30 2016-08-09 International Business Machines Corporation Efficient calibration of a low power parallel data communications channel
US9474034B1 (en) 2015-11-30 2016-10-18 International Business Machines Corporation Power reduction in a parallel data communications interface using clock resynchronization
US10321351B2 (en) 2017-03-02 2019-06-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10492104B2 (en) 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
CA3017210C (en) 2016-03-10 2024-02-13 Cable Television Laboratories, Inc. Systems and methods for latency reduction
BR112018075654B1 (pt) * 2016-06-10 2022-04-05 Veritas Biotecnologia Ltda Anticorpos monoclonais, composições farmacêuticas, linhagem celular de hibridoma, usos dos referidos anticorpos monoclonais e métodos para detectar a expressão de cdh1
US12225536B2 (en) 2016-10-07 2025-02-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10420085B2 (en) 2016-10-07 2019-09-17 Cable Television Laboratories, Inc. System and method for grant assignment
WO2019216925A1 (en) 2018-05-10 2019-11-14 Axon Enterprise, Inc. Systems and methods for cross-redaction
AU2021206586A1 (en) * 2020-01-10 2022-07-21 Kling Biotherapeutics B.V. Epithelial cadherin-specific antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR940009084B1 (ko) 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
WO1994011401A1 (en) 1992-11-17 1994-05-26 Yale University Human homolog of the e-cadherin gene and methods based thereon
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6723320B2 (en) * 1996-07-24 2004-04-20 Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
CA2441626A1 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
CA2513559A1 (en) 2003-01-23 2004-08-05 University Of Rochester Herpesvirus amplicon particles
EP2426149A4 (en) * 2009-05-01 2013-01-23 Univ Tokyo ANTI-CADHERIN ANTIBODY

Also Published As

Publication number Publication date
CA2816358A1 (en) 2012-05-03
KR20140075639A (ko) 2014-06-19
AU2011319777A1 (en) 2013-05-23
SG10202100921YA (en) 2021-03-30
MX357167B (es) 2018-06-28
AU2011319777B2 (en) 2016-12-08
JP6243737B2 (ja) 2017-12-06
WO2012058418A3 (en) 2012-07-19
CN103582494A (zh) 2014-02-12
WO2012058418A2 (en) 2012-05-03
US20130287784A1 (en) 2013-10-31
SG189547A1 (en) 2013-05-31
RU2013123792A (ru) 2014-12-10
ES2784385T3 (es) 2020-09-24
SG10201604467PA (en) 2016-07-28
MX2018007983A (es) 2023-02-23
US20160046701A1 (en) 2016-02-18
US20210380671A1 (en) 2021-12-09
EP2632489A2 (en) 2013-09-04
JP2014500862A (ja) 2014-01-16
US20190352380A1 (en) 2019-11-21
MX2013004790A (es) 2014-01-17
EP2632489A4 (en) 2014-06-18
EP2632489B1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
BR112013010535A2 (pt) composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer
MX373584B (es) Tratamiento de cánceres utilizando moduladores de la isoforma pi3 cinasa.
Chen et al. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro
CL2017001296A1 (es) Anticuerpos contra cd73 y sus usos
BR112013006699A2 (pt) vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
MX369550B (es) Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
BRPI0924123B8 (pt) vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
MX2020004712A (es) Vesiculas extracelulares modificadas geneticamente con proteinas.
Liu et al. Downregulation of reticulocalbin‐1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells
Peng et al. M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and autophagy in HCT116 colon carcinoma cells via blocking PI3K/Akt/mTOR pathway
BR112012013664A2 (pt) rabdovírus oncolítico
MX2015001194A (es) Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
García et al. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
Dong et al. Aging attenuates cardiac contractility and affects therapeutic consequences for myocardial infarction
MX390894B (es) Polipéptido de fusión anti-cáncer.
BR112017003836A2 (pt) processo para sintetizar dna livre de células
BR112018007174A2 (pt) instrumento para higiene bucal com saliências condutoras
BR112015021869A2 (pt) Domínios gla como agentes alvo
Bedal et al. Collagen XVI induces expression of MMP9 via modulation of AP-1 transcription factors and facilitates invasion of oral squamous cell carcinoma
BR102016007036A8 (pt) material de reparo de tecido derivado de pele de peixe e método de fabricação do mesmo
BR112021008774A2 (pt) Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
BR112016007592A2 (pt) proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements